Legato Capital Management LLC Has $2.45 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Legato Capital Management LLC grew its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 48.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,364 shares of the biopharmaceutical company's stock after buying an additional 9,541 shares during the period. Legato Capital Management LLC's holdings in Intra-Cellular Therapies were worth $2,452,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. True Wealth Design LLC acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $32,000. GAMMA Investing LLC increased its stake in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after acquiring an additional 240 shares during the period. Capital Performance Advisors LLP acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $74,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $97,000. Finally, Quarry LP increased its stake in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after acquiring an additional 1,300 shares during the period. Institutional investors own 92.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ITCI. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their price objective for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Needham & Company LLC restated a "hold" rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a research report on Monday, January 13th. Piper Sandler restated a "neutral" rating and issued a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 14th. Finally, StockNews.com began coverage on shares of Intra-Cellular Therapies in a research report on Saturday, February 8th. They issued a "hold" rating on the stock. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of "Moderate Buy" and a consensus target price of $103.62.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company's stock, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 2.60% of the company's stock.

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock traded down $0.24 during midday trading on Friday, reaching $127.82. The stock had a trading volume of 1,382,004 shares, compared to its average volume of 5,987,666. The firm's fifty day simple moving average is $105.80 and its two-hundred day simple moving average is $87.90. Intra-Cellular Therapies, Inc. has a twelve month low of $62.78 and a twelve month high of $128.19. The firm has a market cap of $13.59 billion, a price-to-earnings ratio of -146.92 and a beta of 0.72.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.